Latin America Anti-Obesity Drugs Market Report and Forecast 2024-2032

Latin America Anti-Obesity Drugs Market Outlook

The global anti-obesity drugs market size was valued at USD 2.5 billion in 2023, with Latin America holding a significant market share. It is expected to grow at a CAGR of 10.70% during the forecast period of 2024-2032. The market is poised to secure a value of USD 6.3 billion by 2032, driven by the rising prevalence of obesity among children and teenagers across the region.

Key Takeaways

• According to the report released by the United Nations, Overview of Food Security and Nutrition 2022, almost one-fourth (22.5%) of the Latin American population is unable to afford a healthy meal in comparison to the world approximately priced at USD 3.89 per person per day.

• The increasing prevalence of obesity due to the adaption of a sedentary lifestyle along with unhealthy dietary habits are significant factors driving the Latin America anti-obesity drugs market growth in the forecast period.

• The regional market is witnessing high incidence of anti-obesity drugs, which is likely to boost the market share in the forecast period. In February 2023, Tesofensine received positive opinions from Mexican Food and Drug Administration.

Latin America Anti-Obesity Drugs Market Analysis

Obesity is a growing problem globally and is significantly contributing to high rates of health issues. Therefore, battling this condition is a major necessity of the hour. The Latin American region is facing major health issues related to obesity among children, teenagers, and adults. In August 2023, UNICEF released a report which highlighted that more than 4 million children aged 5 years or less were overweight in Latin American and Caribbean region.

Latin America anti-obesity drugs market share is estimated to be influenced by the approval of drugs by regional regulatory authorities. For instance, in December 2019, Medix, a Mexican pharmaceutical company submitted a New Drug Application (NDA) to the Mexican Food and Drug Administration COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) for the approval of tesofensine (a monoamine uptake inhibitor), which can be used for treating obesity in patients. Tesofensine has demonstrated effective loss results in phase II studies in obese patients. After a long wait, on February 26, 2023, the tesofensine was provided a favourable opinion by the Mexican regulatory authority for the treatment of obese patients. Considering the efficacy provided by tesofensine in the clinical trial, a potential interest from both healthcare providers and patients is anticipated, propelling the market growth. The competitive landscape is also expected to be driven by the approval of tesofensine.

Latin America anti-obesity drugs market demand is likely to be propelled by the alarmingly increasing obesity rates. It has been highlighted that the current prevalence rate in Latin America is above the global average, and it has been rising over the last two decades at a sustained rate. Additionally, it contributes to various other health concerns such as hypertension, high cholesterol, diabetes, cardiovascular disease, and even cancer. Addressing obesity among people at early stages is a major precaution that can play a crucial role in timely treatments and overall increased the life expectancy of obese population in the region.

Latin America Anti-Obesity Drugs Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Latin America Anti-Obesity Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• VIVUS Inc.

• Pfizer, Inc.

• Novo Nordisk

• Bayer AG

• F Hoffmann-La-Roche

• Glaxosmithkline

• Arena Pharmaceuticals

• Eisai Co. Ltd

• Takeda Pharmaceutical Company

• Nalpropion Pharmaceuticals Inc

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report